866-997-4948(US-Canada Toll Free)

B. Braun Melsungen AG - Product Pipeline Analysis

Published By :

GlobalData

Published Date : Nov 2012

Category :

Surgical Equipment

No. of Pages : 83 Pages


B. Braun Melsungen AG (B. Braun) is a global health care company involved in marketing and selling products and services catering to basic healthcare, intensive care units, anesthesia and emergency care sectors. The company also provides solutions for extracorporeal blood treatment and core surgical procedures. The company operates in four business divisions namely, Hospital Care division, which supplies the hospitals with infusion, injection solutions and disposable medical products; Aesculap division, which supplies products and services for all the core processes in surgery; Out Patient Market (OPM) division, which supplies medical products outside the hospital for chronically ill and long term care patients; and B. Braun Avitum division compiles the product and services concerning extra-corporeal blood treatment. It operates worldwide, principally in Europe, Switzerland, the US, Brazil and Malaysia. B. Braun is headquartered in Melsungen, Germany.

The company focuses on innovation of new products which can improve processes in hospitals along end-user safety assurance. This intent is indicated by the companys recently launched FDA approved products such as Introcan Safety 3 Closed IV Catheter and NuTRIflex Omega among others. The company also concentrates on optimizing the hospital processes as seen from the recently issued patents for enhanced communications between medical devices and hospital information management system to the company. In order to enhance this innovation and production, the company has also opened new manufacturing facilities in Vietnam and Switzerland.

This report is a source for data, analysis and actionable intelligence on the B. Braun Melsungen AG portfolio of pipeline products. The report provides detailed analysis on each pipeline product with information on the indication, the development stage, trial phase, product milestones, pipeline territory, estimated approval date, and estimated launch date

Each pipeline product is profiled to cover information on product description, function, technology, indication, and application. The report is also supplemented with a detailed company profile and information on clinical trials, wherever applicable.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalDatas team of industry experts.

Scope

  • Detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments.
  • Detailed coverage on all the pipeline products, by equipment type, by therapy area, by development stage, and by trial phase.
  • Information on product milestones and pipeline territory for each product, the estimated approval date, and estimated launch date.
  • Profile of each pipeline product with additional information on product description, function, technology, indication(s), and application.
  • Data on relevant clinical trials and product patent details, wherever applicable.
  • Information on clinical trial, wherever applicable, is supplemented with information on trial phase, trial status, trial objective, trial design, target patients, unique physician identifier, primary point, secondary point, acronym, participants inclusion, participants exclusion, interventions, trial results, trial start date, trial end date, study type, trial site, trial funding, age eligibility, and gender eligibility.

Reasons to Buy

  • Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape globally.
  • Design and develop your product development, marketing and sales strategies.
  • Exploit M&A opportunities by identifying market players with the most innovative pipeline.
  • Develop market-entry and market expansion strategies.
  • Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return.
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Develop competition strategies by identifying the status and likely launch of your competitors pipeline products through review of the clinical trials, stage and phase of development, etc.Which are the next high-value products that your competitor would add in its portfolio? identify, understand and capitalize.
Table of Content

Table of Contents 2
List of Tables 3
List of Figures 4

B. Braun Melsungen AG - Business Description 5

Key Facts 6
B. Braun Melsungen AG - Major Products and Services 7
B. Braun Melsungen AG Pipeline Products by Equipment Type 11
B. Braun Melsungen AG Pipeline Products by Development Stage 13
B. Braun Melsungen AG Pipeline Products by Therapy Area 15
B. Braun Melsungen AG Pipeline Products by Trial Phase 19
B. Braun Melsungen AG Pipeline Products by Milestone Summary 21
Askina Calgitrol Paste 23
Askina Calgitrol Paste Product Status 23
Askina Calgitrol Paste Product Description 23
Biological Knee Regeneration Device 24
Biological Knee Regeneration Device Product Status 24
Biological Knee Regeneration Device Product Description 24
Needle-Free System 25
Needle-Free System Product Status 25
Needle-Free System Product Description 25
SeQuent Please 26
SeQuent Please Product Status 26
SeQuent Please Product Description 26
SeQuent Please Product Milestone 26
SeQuent Please Clinical Trial 27
SeQuent Please Product Patent Details 69
B. Braun Melsungen AG - Key Competitors 71
B. Braun Melsungen AG - Key Employees 72
B. Braun Melsungen AG - Key Employee Biographies 73
B. Braun Melsungen AG - Locations And Subsidiaries 74
Head Office 74
Other Locations & Subsidiaries 74
Recent Developments 78
B. Braun Melsungen AG, Recent Developments 78
Aug 01, 2012: Telstar Completes Pharmaceutical Manufacturing And Process Facilities For B. Braun\'s New LIFT Plant 78
Mar 09, 2012: B. Braun Melsungen Reports Revenue of 4.6 Billion In 2011 78
Oct 11, 2011: B. Braun Opens Production Plant In Hanoi, Vietnam 79
Oct 11, 2011: B. Braun Melsungen Opens New Production Plant In Hanoi, Vietnam 79
Aug 05, 2011: Terumo Wins Patent Suit Against B.Braun On Intravenous Catheter With Safety Device 80
Aug 01, 2011: B. Braun Melsungen Opens New Company In Serbia 80
Jul 27, 2011: Interlocutory Injunction Order Successfully Defended: B. Braun 81
May 04, 2011: B. Braun Prevails In Case Against Terumo For Introcan Safety IV Catheter Patent 81
Apr 07, 2011: European Patent Office Upholds Earlier Finding Supporting Terumo In Conflict Over B.Braun Patent 81
Apr 01, 2011: B. Braun Announces Board Changes 82

Appendix 83
Methodology 83
About GlobalData 83
Contact Us 83
Disclaimer 83

List of Table


B. Braun Melsungen AG, Key Facts 1
B. Braun Melsungen AG Key Pipeline Products by Equipment Type 1
B. Braun Melsungen AG Key Pipeline Products by Therapy Area 1
B. Braun Melsungen AG Key Pipeline Products by Development Stage 1
B. Braun Melsungen AG Key Pipeline Products by Trial Phase 1
B. Braun Melsungen AG, Key Facts 6
B. Braun Melsungen AG, Major Products and Services 7
B. Braun Melsungen AG Number of Pipeline Products by Equipment Type 11
B. Braun Melsungen AG Pipeline Products by Equipment Type 12
B. Braun Melsungen AG Number of Pipeline Products by Development Stage 13
B. Braun Melsungen AG Pipeline Products by Development Stage 14
B. Braun Melsungen AG Number of Pipeline Products by Therapy Area 15
B. Braun Melsungen AG Pipeline Products by Therapy Area 16
B. Braun Melsungen AG Number of Pipeline Products by Trial Phase 19
B. Braun Melsungen AG Pipeline Products by Trial Phase 20
B. Braun Melsungen AG Number of Pipeline Products By Milestone Summary 21
B. Braun Melsungen AG Pipeline Products by Milestone Summary 22
Askina Calgitrol Paste - Product Status 23
Askina Calgitrol Paste - Product Description 23
Biological Knee Regeneration Device - Product Status 24
Biological Knee Regeneration Device - Product Description 24
Needle-Free System - Product Status 25
Needle-Free System - Product Description 25
SeQuent Please - Product Status 26
SeQuent Please - Product Description 26
SeQuent Please - Product Milestone 26
SeQuent Please - Paclitaxel-Eluting Balloon Angioplasty and Coroflex-Stents In The Treatment Of Bifurcated Coronary Lesions 27
SeQuent Please - Paclitaxel-Eluting PTCA-Balloon In Combination With The Coroflex Blue Stent vs The Sirolimus Coated Cypher Stent In The Treatment Of Advanced Coronary Artery Disease 30
SeQuent Please - The Paclitaxel-Eluting PTCA-Balloon Catheter In Coronary Artery Disease To Treat In-Stent Restenoses: A Comparison To the Paclitaxel-Eluting Taxus Stent. A Pilot Study 32
SeQuent Please - Paclitaxel-Eluting Balloon Angioplasty And Cobalt-Chromium Stents Versus Conventional Angioplasty And Paclitaxel-Eluting Stents In The Treatment Of Native Coronary Artery Stenoses Of Diabetic Patients 35
SeQuent Please - The Paclitaxel-Eluting PTCA-Balloon Catheter In Combination With A Cobalt-Chromium Stent To Treat Coronary Artery Disease In A Real World Scenario 39
SeQuent Please - The Paclitaxel-Eluting PTCA-Balloon Catheter In Coronary Artery Disease To Treat Chronic Total Occlusions 42
SeQuent Please - Healing Responses After Treatment of Bare Metal Stent Restenosis With Implantation of an Everolimus-eluting Xience V Stent Versus Use of a Paclitaxel-eluting Balloon: Optical Coherence Tomography Study 43
SeQuent Please - PEPCAD DES - Treatment of DES-In-Stent Restenosis With SeQuent Please Paclitaxel Eluting PTCA Catheter 45
SeQuent Please - Randomized Trial of Paclitaxel-Eluting Balloon, Paclitaxel-Eluting Stent and Plain Balloon Angioplasty for Restenosis in \"-Limus\"-Eluting Coronary Stents 49
SeQuent Please - DARE-Trial: Drug Eluting bAlloon for In-stent REstenosis. Multi-center, Randomized Trial to Study the Effect of the SeQuent Please Drug-eluting Balloon Versus the Xience Prime Drug-eluting Stent for the Treatment of In-stent Restenosis 50
SeQuent Please - The Paclitaxel-Eluting PTCA-Balloon Catheter for the Treatment of Coronary Bifurcations 52
SeQuent Please - Randomized Trial On The Treatment Of Coronary De-novo Lesions With A Drug Eluting Stent Or A Drug Coated Balloon 54
SeQuent Please - Pressure Wire-guided Percutaneous Coronary Intervention of Small Vessels or Side Branches: Functional Outcome of Drug-Eluting Stent (DES) Versus Drug-Eluting Balloon (DEB) With Provisional Bare Metal Stent Implantation 56
SeQuent Please - RIBS IV (Restenosis Intra-stent of Drug-eluting Stents: Paclitaxel-eluting Balloon vs Everolimus-eluting Stent). A Prospective, Multicenter and Randomized Clinical Trial 58
SeQuent Please - Bare Metal Stent Versus Drug Coated Balloon With Provisional Stenting in Non-ST-Elevation Myocardial Infarction 60
SeQuent Please - Comparison of Drug-Eluting Balloon First and Then Bare Metal Stent With Drug-eluting Stent for Treatment of de Novo Lesions (DEB First): A Randomized Controlled Single Center Clinical Trial 61
SeQuent Please - Safety and Efficacy: Paclitaxel-Eluting Balloon SeQuent Please Shows Positive Results in Largest Real World International Registry 63
SeQuent Please - Prospective Randomized Study of the Paclitaxel-Coated Balloon Catheter in Bifurcated Coronary Lesions / BABILON Study (Paclitaxel-Coated Balloon in Bifurcated Lesions) 64
SeQuent Please - A Prospective, Randomized, Controlled, Open Label, Multicenter Trial to Test the Non-inferiority of Drug Eluting Balloon vs. Drug Eluting Stent Treatment in de Novo Stenoses of Small Native Vessels Regarding Efficacy and Safety 65
SeQuent Please - A Multicenter, Randomized, Open Lable, Active Controlled Clinical Study To Evaluate The Safety And Efficacy Of The Treatment Of In-Stent Restenosis Lesion By Paclitaxel-Eluting PTCA- Balloon Catheter (Sequent Please) Versus Paclitaxel-Eluting Stent (Taxus Liberte) 66
SeQuent Please - A Multicenter, Randomized, Open, Active Controlled Clinical Study to Evaluate the Safety and Efficacy of the Treatment of In-stent Restenosis Lesion by Paclitaxel-eluting PTCA- Balloon Catheter Versus Paclitaxel-eluting Stent 67
SeQuent Please - Effectiveness of Paclitaxel-eluting Balloon Catheter in Patients with Sirolimus-eluting Stent Restenosis 68
SeQuent Please - Patent Details1 69
SeQuent Please - Patent Details2 70
B. Braun Melsungen AG, Key Employees 72
B. Braun Melsungen AG, Key Employee Biographies 73
B. Braun Melsungen AG, Other Locations 74
B. Braun Melsungen AG, Subsidiaries 75

List of Chart


B. Braun Melsungen AG Pipeline Products by Equipment Type 11
B. Braun Melsungen AG Pipeline Products by Development Stage 13
B. Braun Melsungen AG Pipeline Products by Therapy Area 15
B. Braun Melsungen AG Pipeline Products by Trial Phase 19
B. Braun Melsungen AG Pipeline Products by Milestone Summary 21

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *